Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
3.780
+0.330 (9.57%)
At close: Jun 26, 2026, 4:00 PM EDT
3.770
-0.010 (-0.26%)
After-hours: Jun 26, 2026, 7:46 PM EDT
Verastem Employees
Verastem had 102 employees as of December 31, 2025. The number of employees increased by 24 or 30.77% compared to the previous year.
Employees
102
Change (1Y)
24
Growth (1Y)
30.77%
Revenue / Employee
$486,127
Profits / Employee
-$1,901,559
Market Cap
332.16M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Abeona Therapeutics | 226 |
| Rocket Pharmaceuticals | 202 |
| Lineage Cell Therapeutics | 77 |
| Immuneering | 55 |
| Atea Pharmaceuticals | 55 |
| Inhibikase Therapeutics | 35 |
| DiaMedica Therapeutics | 35 |
VSTM News
- 4 days ago - Verastem Transcript: Study update - Transcripts
- 4 days ago - Verastem Press release: Study update - Filings
- 4 days ago - Verastem Slides: Study update - Filings
- 4 days ago - Verastem reports ‘positive’ preliminary data from ongoing TARGET-D trial - TheFly
- 4 days ago - VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors - Business Wire
- 4 days ago - Verastem price target lowered to $8 from $15 at Jefferies - TheFly
- 10 days ago - Verastem announces safety, efficacy results from RAMP 205 Phase 1b/2a study - TheFly
- 10 days ago - Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer - Business Wire